
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
NOVN | Switzerland | CHF | Delayed | |
NOVNz | BATS Europe | CHF | Delayed | |
NVS | NYSE | USD | Real-time | |
NVSEF | OTC Markets | USD | Delayed | |
0QLR | London | CHF | Real-time | |
NVSN | Mexico | MXN | Delayed | |
NOVZn | TradeGate | EUR | Delayed | |
NOVZn | Frankfurt | EUR | Delayed | |
NVS-RMDR | Moscow | RUB | Real-time |
The U.S.-listed shares of Novartis AG fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was "temporarily" suspending delivery of its cancer treatments Lutathera...
Novartis AG (NYSE: NVS) has announced updated median overall survival (OS) results for Kisqali (ribociclib) combined with fulvestrant for postmenopausal women with hormone receptor-positive, human...
Novartis AG (NYSE: NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data...
Molecular Partners AG (NASDAQ: MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says...
Novartis AG (NYSE: NVS) has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44. Net income reached $2.2 billion, an increase of 8% or 15% at constant...
Novartis posts higher net profit of $2.22 billion on sales of $12.53 billion
(Reuters) – Core operating income at Novartis edged 3% higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease Aeglea BioTherapeutics...
ZURICH (Reuters) – Swiss drugmaker Novartis will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a reorganisation announced last week, Swiss newspaper...
The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS)...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review